Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Traws Pharma, Inc. (NASDAQ: TRAW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Traws’ clinical-stage antiviral programs, financial position, governance and executive compensation, and they complement the company’s press releases.
Through periodic reports such as the Form 10-K and proxy statements, Traws describes its business focus on developing investigational oral small molecule antivirals for respiratory viral diseases, including COVID-19, Long COVID, bird flu and seasonal influenza. The definitive proxy statement (DEF 14A) outlines board structure, incentive compensation plans and matters submitted to stockholders, while also providing context on corporate governance and director elections.
Current reports on Form 8-K, several of which are referenced in the provided data, document material events such as interim clinical data announcements for ratutrelvir, approval to proceed with Phase 2 COVID-19 studies, dosing of the first Phase 2 subjects, quarterly earnings releases, option and restricted stock unit grants to executives, and the appointment of new board members and officers. These filings also confirm that Traws’ common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
Investors and analysts can use this page to review how Traws reports on its clinical progress with ratutrelvir and tivoxavir marboxil, its legacy oncology programs rigosertib and narazaciclib, and its financial results and capital structure. Forms related to executive and director compensation, incentive plans and governance changes provide additional insight into how the company aligns management incentives with its development priorities.
Stock Titan enhances access to these filings by organizing them chronologically and by form type, and by offering AI-powered summaries that explain the key points of lengthy documents such as annual reports, quarterly updates and 8-Ks. This allows users to quickly understand the significance of new filings, track trends in Traws’ disclosures and identify items such as clinical milestones, financing arrangements or changes in leadership that may be important for evaluating TRAW stock.
Schedule 13G filed for Traws Pharma, Inc. (TRAW) reports that Squadron Master Fund LP holds 372,374 shares (5.3%) and that Squadron Capital Management LLC and principals Matthew Sesterhenn and William Blank each report 420,501 shares (6.0%) based on 7,063,829 shares outstanding as of August 12, 2025. The filing states the shares are held by funds advised by Squadron Capital and that the adviser and the named partners disclaim beneficial ownership under Rule 13d-4. No party reports sole voting or dispositive power; all reported holdings are shared.
Traws Pharma, Inc. filed a current report to highlight new investor communications and a clinical milestone. The company has begun using a new corporate presentation, which is furnished as an exhibit and posted on its website.
The report also notes a press release announcing that a Human Research Ethics Committee has approved proceeding with a Phase 2 study of ratutrelvir, a ritonavir-free treatment in newly diagnosed COVID subjects. The press release and the investor presentation are attached as Exhibits 99.1 and 99.2.
Traws Pharma, Inc. furnished an earnings press release announcing its financial results for the quarter ended June 30, 2025, and began using a new corporate investor presentation. The earnings release is furnished as Exhibit 99.1 and the presentation as Exhibit 99.2, and the presentation will be posted on the company website.
The disclosure in Item 7.01 is incorporated by reference into Item 2.02 but is explicitly furnished, not filed, and therefore is not subject to Section 18 liabilities or automatically incorporated by reference in other filings unless specifically referenced. The Current Report and its exhibits include customary forward‑looking statements and a risk disclaimer. The 8‑K body does not contain numeric financial results; investors must review Exhibits 99.1 and 99.2 for the full figures and context.
Traws Pharma, Inc. completed an April 2024 asset acquisition of Trawsfynydd and now focuses on two lead antiviral programs, tivoxavir marboxil and ratutrelvir, while retaining oncology assets for potential partnerships. The asset acquisition included an in‑process R&D asset valued at $117.464 million.
For the three months ended June 30, 2025 the company reported $2.733 million of revenue and a net loss of $0.915 million; for the six months ended June 30, 2025 it reported $2.79 million of revenue and net income of $20.575 million, largely reflecting recognition of deferred revenue and significant changes and reclassifications of warrant liabilities. Cash and cash equivalents were $13.081 million at June 30, 2025 and the company stated it does not have sufficient cash to support operations for more than one year, noting substantial doubt about its ability to continue as a going concern. The company regained Nasdaq compliance with minimum stockholders’ equity and will be subject to a mandatory panel monitor for one year.
Traws Pharma (NASDAQ:TRAW) filed a routine Form 4 disclosing that director Clarke Trafford was granted 23,000 stock options on 06/19/2025. The options carry a $1.65 exercise price, vest 100 % after one year (06/19/2026) and expire on 06/19/2035. Following the grant, the reporting person now beneficially owns 23,000 derivative securities directly. No shares of common stock were bought or sold, and there are no indications of 10b5-1 trading plans or additional transactions in this filing.
Traws Pharma (NASDAQ:TRAW) filed a routine Form 4 reporting an insider equity grant. Director Jack E. Stover received 23,000 non-qualified stock options on 06/19/2025 at an exercise price of $1.65 per share. The options vest 100 % on the first anniversary of the grant date and expire on 06/19/2035. No open-market purchases or sales of common stock were disclosed, and the grant carries no immediate cash value to the director. Following the transaction, Stover beneficially owns 23,000 derivative securities, all held directly.
Traws Pharma (NASDAQ:TRAW) filed a routine Form 4 reporting that director Mary Teresa Shoemaker received 23,000 stock options on 06/19/2025 at an exercise price of $1.65 per share. The options vest 100% on the first anniversary of the grant date and expire on 06/19/2035. No shares were sold and no other material changes were disclosed.
Traws Pharma (TRAW) filed a routine Form 4 reporting that director Werner Cautreels received 23,000 stock options on 06/19/2025 at an exercise price of $1.65. The options vest 100% on the first anniversary of the grant date and expire on 06/19/2035. No common shares were bought or sold, and beneficial ownership remains unchanged apart from the new option grant.
FAQ
What is the current stock price of Traws Pharma (TRAW)?
What is the market cap of Traws Pharma (TRAW)?
